-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25

Benzinga·11/14/2025 14:29:37
Listen to the news
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Overweight rating and announces Price Target of $25.